Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RAPT THERAPEUTICS INC.
RAPT | US
1.65
USD-0.14
-8.10%
RAPT | US
About RAPT THERAPEUTICS INC.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.65
Open
1.79
High
1.82
Low
1.64
RAPT Therapeutics Inc. a clinical-stage immunology-based biopharmaceutical company focuses on discovery development and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193 a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475 an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio Inc. and changed its name to RAPT Therapeutics Inc. in May 2019. RAPT Therapeutics Inc. was incorporated in 2015 and is headquartered in South San Francisco California.
View LessRAPT | US
Risk
123.8
Sharpe
-0.73
Luna's Score
40/100
Recommendation
Sell
Luna says (RAPT | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
100.7%1 month
123.8%3 months
95.4%6 months
100.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.54
Debt to equity
0.05
Debt to assets
0.05
Ent. to EBITDA
-10.73
Ent. to rev.
677.37
PEG
-
Other Fundamentals
EBITDA
-127.72M
MarketCap
57.42M
MarketCap(USD)
57.42M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-77.98
Short ratio
11.99
Short perc.
12.09
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.45
Range1M
0.71
Range3M
1.84
Volumes: Market Activity
Rel. volume
0.97
Price X volume
365.77K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -10.73 | - | Cheaper |
| Ent. to Revenue | 677.37 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.54 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 95.44 | - | Riskier |
| Debt to Equity | 0.05 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 57.42M | - | Emerging |
